JPMorgan Starts Sage Therapeutics (SAGE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Leerink Swann Starts Sage Therapeutics (SAGE) at Outperform
August 12, 2014 7:46 AM EDTLeerink Swann initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $46.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Sage Therapeutics (SAGE) at Buy
August 12, 2014 7:45 AM EDT(Updated - August 12, 2014 11:16 AM EDT)
Canaccord Genuity initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $40.00.
Analyst John Newman said, "We are initiating coverage on SAGE Therapeutics... More
Goldman Sachs Starts Sage Therapeutics (SAGE) at Neutral
August 12, 2014 7:44 AM EDTGoldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Neutral rating and a price target of $38.00.
Analyst Navdeep Singh said, "Sage is a small-cap biotech focused on developing drugs for central nervous... More
